Two sofosbuvir containing regimens in egyptian hepatitis c related compensated liver cirrhosis: Impact on clinical outcome and liver stiffness

Background/Aim: The current study aimed to evaluate the impact of sustained virological response (SVR) after two sofosbuvir (SOF) containing regimens on the clinical outcomes, non invasive markers of hepatic fibrosis and liver stiffness. Patients and Methods: The study included 200 patients with compensated HCV cirrhosis. Group 1: received SOF and Ribavirin (RBV) for 6 months, Group 2: received SOF, Daclatsvir (DAC) and RBV for 3 months. Hepatitis C Virus Ribonucleic Acid (HCV RNA) by Polymerase Chain Reaction (PCR) was done at baseline, end of treatment (EOT), SVR12, SVR48. Model for end stage liver disease (MELD) score was calculated, the aspartate aminotransferase to platelet ratio index (APRI) and Fibrosis-4 (FIB-4) scores were done. FibroScan was done at baseline and SVR48. Results: SVR12 occured in 75% and 96% in group 1 and 2, respectively. There was improvement in both of APRI and FIB-4 scores at EOT in the two groups, and maintained to SVR48. A significant improvement in mean liver stiffness (LS) occurred at SVR48 compared to baseline in the study groups. Improvement in LS was observed more in group 2. There was a significant decrease in the mean value of MELD score in group 2 and non-significant decrease in group 1 at SVR48 in comparison to pre-treatment mean value. Conclusion: SOF/DAC/RBV was effective treatment regimen in compensated liver cirrhosis. This regimen resulted in significant improvement in MELD score, and liver stiffness at SVR48.